Teri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Vaxcyte Stock Down 2.9 %

PCVX stock opened at $85.30 on Friday. The firm has a market cap of $10.63 billion, a price-to-earnings ratio of -18.54 and a beta of 0.98. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06. The business’s fifty day simple moving average is $88.08 and its two-hundred day simple moving average is $93.55.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the company posted ($0.91) earnings per share. Research analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Institutional Trading of Vaxcyte

Several institutional investors and hedge funds have recently modified their holdings of PCVX. Riverview Trust Co bought a new position in Vaxcyte in the third quarter worth approximately $27,000. Blue Trust Inc. grew its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares in the last quarter. Meeder Asset Management Inc. increased its stake in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after buying an additional 635 shares during the period. Nomura Asset Management Co. Ltd. bought a new stake in shares of Vaxcyte in the third quarter valued at about $92,000. Finally, Signaturefd LLC lifted its stake in Vaxcyte by 51.9% in the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock worth $120,000 after acquiring an additional 358 shares during the period. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.